Sulphated Polymers are Potent and Selective Inhibitors of Various Enveloped Viruses,Including Herpes Simplex Virus,Cytomegalovirus,Vesicular Stomatitis Virus,Respiratory Syncytial Virus,and Toga-,Arena- and Retroviruses
Free accessResearch articleFirst published online August, 1990
Sulphated Polymers are Potent and Selective Inhibitors of Various Enveloped Viruses,Including Herpes Simplex Virus,Cytomegalovirus,Vesicular Stomatitis Virus,Respiratory Syncytial Virus,and Toga-,Arena- and Retroviruses
The sulphated polymers, such as polyvinylalcohol sulphate (PVAS) and its co-polymer with acrylic acid (PAVAS), have proved to be potent inhibitors for herpes simplex virus, human cytomegalovirus, vesicular stomatitis virus, respiratory syncytial virus, Sindbis virus, Semliki Forest virus, Junin virus, Tacaribe virus, murine sarcoma virus and human immunodeficiency virus. They are not inhibitory to non-enveloped viruses, such as poliovirus and reovirus. The broad-spectrum antiviral effects of these compounds depend on their molecular weight and degree of sulphation. Pharmacokinetic studies in rabbits have indicated that after intravenous bolus injection the serum concentrations of these compounds decay biphasically, with an initial half-life of approximately 90–120 min.
References
1.
BabaM.NakajimaM.ScholsD.PauwelsR.BalzariniJ., and De ClercqE. (1988a) Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res9: 335–343.
2.
BabaM.PauwelsR.BalzariniJ.ArnoutJ.DesmyterJ., and De ClercqE. (1988b) Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA85: 6132–6136.
3.
BabaM.SnoeckR.PauwelsR., and De ClercqE. (1988c) Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus and human immunodeficiency virus. Antimicrob Agents Chemother32: 1742–1745.
4.
BabaM.ScholsD.De ClercqE.PauwelsR.NagyM.Györgyi-EdelényiJ.LöwM., and GörögS. (1990) Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation. Antimicrob Agents Chemother34: 134–138.
5.
BalzariniJ.NaesensL.HerdewijnP.RosenbergI.HolyA.PauwelsR.BabaM.JohnsD.G., and De ClercqE. (1989) Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA86: 332–336.
6.
Barré-SinoussiF.ChermannJ.C.ReyF.NugeyreM.T.ChamaretS.GruestJ.DauguetC.Axler-BlinC.Vézinet-BrunF.RouziouxC.RozenbaumW., and MontagnierL. (1983) Isolation of a T lymphotropic retrovirus from a patient at risk for AIDS. Science220: 868–871.
7.
DalgleishA.G.BeverleyP.C.L.ClaphamP.R.CrawfordD.H.GreavesM.P., and WeissR.A. (1984) The CD4(T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature312: 763–766.
8.
De ClercqE., and MeriganT.C. (1971) Moloney sarcoma virus-induced tumors in mice: inhibition or stimulation by (poly rI). (poly rC). Proc Soc Exp Biol Med137: 590–593.
9.
De ClercqE.DescampsJ.VerhelstG.WalkerR.T.JonesA.S.TorrenceP.F., and ShugarD. (1980) Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis141: 563–574.
10.
HaseltineW.B. (1988) Replication and pathogenesis of the AIDS virus. J Acquir Immune Defic Syndr1: 217–240.
11.
HosoyaM.ShigetaS.NakamuraK., and De ClercqE. (1989) Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in vitro. Antiviral Res12: 87–98.
12.
ItoM.BabaM.SatoA.PauwelsR.De ClercqE., and ShigetaS. (1987) Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficieny virus (HIV) in vitro. Antiviral Res7: 361–367.
13.
ItoM.BabaM.HirabayashiK.MatsumotoT.SuzukiM.SuzukiS.ShigetaS., and De ClercqE. (1989) In vitro activity of mannan sulfate, a novel sulfated polysaccharide, against human immuno-deficiency virus type 1 and other enveloped viruses. Eur J Clin Microbiol Infect Dis8: 171–173.
14.
JohnsonR.P., and SchooleyR.T. (1989) Update on antiviral agents other than zidovudine. AIDS3: S145–S151.
15.
KawanaF.ShigetaS.HosoyaM.SuzukiH., and De ClercqE. (1987) Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob Agents Chemother31: 1225–1230.
16.
LifsonJ.D.ReyesG.R.McGrathM.S.SteinB.S., and EnglemanE.G. (1986a) AIDS retrovirus induced cytopathogenicity: giant cell formation and involvement of CD4 antigen. Science232: 1123–1127.
17.
LifsonJ.D.FeinbergM.B.ReyesG.R.RabinL.R.BanapourB.ChakrabartiS.MossB.Wong-StaalF.SteimerK., and EnglemanE.G. (1986b) Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature323: 725–728.
18.
MachovichR.NagyM.Györgyi-EdelényiCsomorK., and HorváthI. (1986) Anticoagulant effect of sulphated poly(vinylalcohol-acrylic acid)copolymers. Thromb Haemost56: 397–400.
19.
MitsuyaH.LooneyD.J.KunoS.UenoR.Wong-StaalF., and BroderS. (1988) Dextran sulphate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science240: 646–649.
20.
MiyoshiI.TaguchiH.KubonishiI.YoshimotoS.OhtsukiY.ShiraishiY., and AkagiT. (1982) Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr28: 219–228.
21.
NakashimaH.YoshidaO.BabaM.De ClercqE., and YamamotoN. (1989) Anti-HIV activity of dextran sulphate as determined under different experimental conditions. Antiviral Res11: 233–246.
22.
PauwelsR.BalzariniJ.BabaM.SnoeckR.ScholsD.HerdewijnP.DesmyterJ., and De ClercqE. (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Meth20: 309–321.
23.
PopovicM.SarngadharanM.G.ReadE., and GalloR.C. (1984) Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science224: 497–500.
24.
ReichertC.M.StrausS.E.LongoD.L.ParrilloJ.LaneH.C.FauciA.S.RockA.H.ManischewitzJ.F., and QuinnanG.V.Jr. (1983) Death in the AIDS patients: role of cytomegalovirus. New Engl J Med309: 1454.
25.
ScholsD.BabaM.PauwelsR., and De ClercqE. (1989a) Flow cytometric method to demonstrate whether anti-HIV-1 agents inhibit virion binding to T4+ cells. J Acquir Immune Defic Syndr2: 10–15.
26.
ScholsD.PauwelsR.BabaM.DesmyterJ., and De ClercqE. (1989b) Syncytium formation and destruction of bystander CD4+ cells cocultured with T cells persistently infected with human immunodeficiency virus as demonstrated by flow cytometry. J Gen Virol70: 2397–2408.
27.
ScholsD.PauwelsR.DesmyterJ., and De ClercqE. (1990a) Dextran sulphate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotien of persistently HIV-1 infected cells. Virology175: 556–561.
28.
ScholsD.PauwelsR.DesmysterJ., and De ClercqE. (1990b) Flow cytometric method to monitor the destruction of CD4+ cells following their fusion with HIV-infected cells. Cytometry11: 736–743.
29.
ShigetaS.KonnoK.YokotaT.NakamuraK., and De ClercqE. (1988) Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro. Antimicrob Agents Chemother32: 902–911.
30.
SkinnerM.A.TingR.LangloisA.J.WeinholdK.J.LyerlyH.K.JavaherianK., and MatthewsT.J. (1988) Characteristics of a neutralizing monoclonal antibody to HTLV-IIIB envelope glycoprotein. AIDS Res Hum Retroviruses4: 187–197.
31.
SnoeckR.SakumaT.De ClercqE.RosenbergI., and HolyA. (1988) (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother32: 1839–1844.
32.
SodroskiJ.GohW.C.RosenC.CampbellK., and HaseltineW.A. (1986) Role of the HTLV-III/LAV envelope in syncytium formation and cytopathogenicity. Nature322: 470–474.
33.
UenoR., and KunoS. (1987) Dextran sulfate, a potent anti-HIV agent in vitro having synergism with zidovudine. Lanceti: 1379.
34.
WitvrouwM.BabaM.BalzariniJ.PauwelsR., and De ClercqE. (1990) Establishment of a bioassay to determine serum levels of dextran sulfate and pentosan polysulfate, two potent inhibitors of human immunodeficiency virus. J Acquir Immune Defic Syndr3: 343–347.
